Peanut Allergy Pipeline Analysis Report 2025

Peanut allergy is a common and potentially life-threatening condition caused by an immune system overreaction to peanut proteins. This allergy affects around 1 in 50 children globally and accounts for a significant percentage of severe food-related allergic reactions, including anaphylactic shock. There is a high unmet clinical need for better therapies, as current options, such as strict allergen avoidance and emergency epinephrine use, are inadequate for long-term management. The growing focus on innovative treatments, such as oral immunotherapy, biologics, and desensitization therapies, coupled with increasing research funding, is expected to drive significant advancements in the peanut allergy drug pipeline in the coming years.

Report Coverage

The Peanut Allergy Drug Pipeline Insight Report by the publisher gives comprehensive insights into peanut allergy therapeutics currently undergoing clinical trials. It covers various aspects related to the details of each of these drugs under development for peanut allergy. The peanut allergy report assessment includes the analysis of over 100 pipeline drugs and 50+ companies. The peanut allergy pipeline landscape will include an analysis based on efficacy and safety measure outcomes published for the trials, including their adverse effects on patients suffering from the condition, and alignment with peanut allergy treatment guidelines to ensure optimal care practices.

The assessment part will include a detailed analysis of each drug, drug class, clinical studies, phase type, drug type, route of administration, and ongoing product development activities related to peanut allergy.

Peanut Allergy Pipeline Outlook

Peanut allergy is a hypersensitive immune reaction to peanut proteins, occurring when the immune system mistakenly identifies them as harmful. This leads to the release of chemicals like histamine, triggering symptoms ranging from mild hives to severe anaphylaxis. The growing pipeline includes innovative immunotherapies, biologics, and desensitization treatments aimed at providing long-term relief and reducing the risk of severe reactions. Continued research and development are critical in addressing this life-threatening condition.

Currently, peanut allergy treatments focus on allergen avoidance and managing symptoms during exposure, often with antihistamines or epinephrine auto-injectors. Emerging therapies include oral immunotherapy to desensitize patients and biologics targeting immune pathways to prevent reactions. These advancements promise improved safety and quality of life for individuals living with this allergy.

Peanut Allergy Epidemiology

According to a report, the global prevalence of peanut allergy varies significantly, with the highest rates observed in Westernized countries like the United States and the United Kingdom, where 1-2% of the population is affected. In contrast, countries like France report lower rates (0.3-0.7%), while peanut allergy remains rare in Asia, where peanuts are less commonly identified as a primary allergen.

Peanut Allergy - Drug Pipeline Therapeutic Assessment

This section of the report covers the analysis of peanut allergy drug candidates based on several segmentations, including:

By Phase

• Late-Stage Products (Phase 3 and Phase 4)
• Mid-Stage Products (Phase 2)
• Early-Stage Products (Phase I)
• Preclinical and Discovery Stage Products

By Drug Class

• Small Molecules
• Biologics
• Immunotherapies
• Peptide-Based Therapies

By Route of Administration

• Oral
• Parenteral
• Others

Peanut Allergy - Pipeline Assessment Segmentation, By Phases

The report covers phase I, phase II, phase III, phase IV, and early-phase drugs. The coverage includes an in-depth analysis of each drug across these phases. According to analysis, phase II covers a major share of the total peanut allergy clinical trials.

Peanut Allergy - Pipeline Assessment Segmentation, By Drug Classes

The drug molecule categories covered under the peanut allergy pipeline analysis include small molecules, biologics, immunotherapies, and peptide-based therapies. The report provides a comparative analysis of the drug classes for each drug in various phases of clinical trials for peanut allergy.

Peanut Allergy Clinical Trials Therapeutic Assessment - Competitive Dynamics

The peanut allergy drug report insights include the profile of key companies involved in clinical trials and their drugs under development. Below is the list of a few players involved in peanut allergy clinical trials:

• Novartis Pharmaceuticals
• DBV Technologies
• ALK-Abelló A/S
• Allergy Therapeutics PLC
• IgGenix Australia Pty Ltd.
• InnoUp Farma S.L.
• Aravax Pty Ltd.
• Parexel
• Genentech, Inc.
• Regeneron Pharmaceuticals

Peanut Allergy Emerging Drugs Profile

This section covers the detailed analysis of each drug under multiple phases, including phase I, phase II, phase III, phase IV, and emerging drugs for peanut allergy. It includes product description, trial ID, study type, drug class, mode of administration, and recruitment status of peanut allergy drug candidates.

Drug: DBV712

The Phase 3 VITESSE study, sponsored by DBV Technologies, aims to evaluate the safety and efficacy of daily DBV712 (250 mcg) in desensitizing peanut-allergic children aged 4-7 years. This double-blind, placebo-controlled trial, involving around 600 participants, began in February 2023 and is expected to complete primary data collection by November 2025, with full study completion anticipated by October 2029.

Drug: Remibrutinib

Novartis Pharmaceuticals is sponsoring a Phase 2 study to evaluate remibrutinib’s efficacy, safety, and tolerability in adults with peanut allergies. The study involves an estimated 72 participants undergoing oral food challenges to assess tolerance to peanut protein. Scheduled for completion by March 8, 2025, this clinical trial aims to advance treatment options for this life-threatening condition.

Drug: IGNX001

IgGenix Australia Pty Ltd is sponsoring a Phase 1 clinical trial to evaluate the safety, tolerability, pharmacokinetics, and pharmacodynamics of IGNX001 in peanut-allergic adults and older adolescents. This randomized, double-blind, placebo-controlled study involves about 24 participants. Initiated in September 2024, the study is expected to conclude by October 2025.

Reasons To Buy This Report

The Peanut Allergy Drug Pipeline Insight Report provides a strategic overview of the latest and future landscape of treatments for peanut allergy. It provides necessary information for making informed investment decisions along with research, development, and strategic planning efforts. The stakeholders will benefit from the essential insights into peanut allergy collaborations, regulatory environments, and potential growth opportunities.

Key Questions Answered in the Peanut Allergy - Pipeline Insight Report

• Which companies/institutions are leading the peanut allergy drug development?
• What is the efficacy and safety profile of peanut allergy pipeline drugs?
• Which company is leading the peanut allergy pipeline development activities?
• What is the current peanut allergy commercial assessment?
• What are the opportunities and challenges present in the peanut allergy drug pipeline landscape?
• What is the efficacy and safety profile of peanut allergy pipeline drugs?
• Which company is conducting major trials for peanut allergy drugs?
• Which companies/institutions are involved in peanut allergy collaborations aimed at providing enhanced therapeutic alternatives for patients?
• What are the geographies covered for clinical trials in peanut allergy?

This product will be delivered within 3-5 business days.